Nancy Retzlaff, has filed a federal complaint against Turing Pharmaceuticals, the New York Times reports. » Read More
By: Dan Mangan
Mylan raised the prices of 24 drug products more than 20 percent. One went up by 542 percent. Another by 444 percent. » Read More
CEO Brent Saunders spoke after Pfizer and Allergan terminated their $160B merger because of surprise changes in U.S. tax regulations.
Almost 90 percent of doctors' visits are booked over the phone, even as online scheduling dominates many other services.
Out-of-pocket health costs, such as prescriptions, can eat up a lot of retirement savings. Here are four tips for trimming drug expenses.
Hangover Heaven is a start-up using a former gospel choir tour bus to cure people dealing with the night before. Here's how it works.
Could a robotic seal help elderly patient suffering from dementia? It's possible, according to a study released by Front Porch.
Billionaire investor William Ackman faced close questioning on Wednesday when he detailed his hedge fund's biggest-ever quarterly loss.
A failed $160 billion merger between Pfizer and Allergan left experts contemplating whether more deals could be hit by new tax rules.
Valeant Pharmaceuticals said a committee completed a review of its accounting practices and did not find anything that would require restatements.
Republican presidential candidates say they want to dismantle the Affordable Care Act. But investors might not be buying the rhetoric.
The "Fast Money" traders give their final trades of the day.
Zika shouldn't have caught us by surprise, writes Dr. Claire Pomeroy. Here's what needs to be done to prevent the next killer virus.
The U.S. has a long way to go as it tries to a solution to the spread of Zika, CDC Director Thomas Frieden says.
For the first time, the number of obese people around the world now is greater than the number of undernourished, according to a study in The Lancet.
Hollywood star Whoopi Goldberg is launching a line of female-focused cannabis products aimed at relieving menstrual pain.
GlaxoSmithKline is to adopt a graduated approach to patenting its medicines depending on the wealth of different countries.
It's hoped the FDA will approve an artificial pancreas in 2017. The device is expected to transform treatment of type 1 diabetes.
Get the best of CNBC in your inbox